FY2026 Earnings Forecast for ARWR Issued By Zacks Research

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Stock analysts at Zacks Research upped their FY2026 earnings per share (EPS) estimates for Arrowhead Pharmaceuticals in a report issued on Wednesday, August 5th. Zacks Research analyst D. Bautz now expects that the biotechnology company will earn ($3.45) per share for the year, up from their previous forecast of ($3.75). The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($3.51) per share. Zacks Research also issued estimates for Arrowhead Pharmaceuticals’ Q4 2026 earnings at ($1.35) EPS.

Other equities research analysts have also issued reports about the stock. Morgan Stanley raised their price target on shares of Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. B. Riley Financial boosted their price objective on shares of Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Leerink Partners upped their price objective on shares of Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the company a “market perform” rating in a research report on Wednesday, June 17th. Royal Bank Of Canada raised their target price on Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the company an “outperform” rating in a research note on Friday, May 8th. Finally, Piper Sandler restated an “overweight” rating and set a $126.00 target price (up from $110.00) on shares of Arrowhead Pharmaceuticals in a research note on Thursday, July 23rd. Nine investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $97.33.

Arrowhead Pharmaceuticals Trading Up 1.0%

NASDAQ ARWR opened at $89.24 on Monday. The company’s fifty day simple moving average is $80.60 and its 200-day simple moving average is $71.80. Arrowhead Pharmaceuticals has a 52 week low of $17.22 and a 52 week high of $95.49. The company has a current ratio of 5.90, a quick ratio of 5.90 and a debt-to-equity ratio of 1.77. The stock has a market cap of $12.57 billion, a P/E ratio of -39.66 and a beta of 1.27.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). The company had revenue of $75.25 million during the quarter, compared to analysts’ expectations of $44.17 million. Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%.The firm’s revenue was up 171.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.26) EPS.

Institutional Trading of Arrowhead Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Tsfg LLC acquired a new stake in shares of Arrowhead Pharmaceuticals in the 4th quarter valued at about $25,000. Optiver Holding B.V. grew its stake in Arrowhead Pharmaceuticals by 83.8% in the first quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 186 shares in the last quarter. Versant Capital Management Inc increased its holdings in Arrowhead Pharmaceuticals by 285.1% in the second quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 248 shares during the last quarter. Carolina Wealth Advisors LLC increased its holdings in Arrowhead Pharmaceuticals by 80.6% in the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 154 shares during the last quarter. Finally, iSAM Funds UK Ltd bought a new stake in Arrowhead Pharmaceuticals in the third quarter valued at about $29,000. 62.61% of the stock is owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.